Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE HIVES.
BROMPHENIRAMINE MALEATE vs CETIRIZINE HYDROCHLORIDE HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Selective inverse agonist of histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and gastrointestinal tract.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life is approximately 8–11 hours in healthy adults (mean ~8.3 h). In renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 20–30 hours, requiring dose adjustment.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Approximately 70% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion, with about 10% excreted in feces. Biliary elimination is minimal.
Category C
Category A/B
Antihistamine
Antihistamine